tetano
Editor, Senior Moderator
Sci Rep
. 2021 Dec 13;11(1):23874.
doi: 10.1038/s41598-021-02534-2.
Statin Use and In-hospital Mortality in Patients with COVID-19 and Coronary Heart Disease
Lan Shen[SUP] #[/SUP][SUP] 1 [/SUP], Lin Qiu[SUP] #[/SUP][SUP] 2 [/SUP], Li Wang[SUP] #[/SUP][SUP] 3 [/SUP], Hengye Huang[SUP] #[/SUP][SUP] 4 [/SUP], Dong Liu[SUP] 2 [/SUP], Ying Xiao[SUP] 2 [/SUP], Yi Liu[SUP] 2 [/SUP], Jingjin Jin[SUP] 2 [/SUP], Xiulan Liu[SUP] 2 [/SUP], Dao Wen Wang[SUP] 5 [/SUP], Ben He[SUP] 6 [/SUP], Ning Zhou[SUP] 7 [/SUP]
Affiliations
Abstract
The worsening progress of coronavirus disease 2019 (COVID-19) is attributed to the proinflammatory state, leading to increased mortality. Statin works with its anti-inflammatory effects and may attenuate the worsening of COVID-19. COVID-19 patients were retrospectively enrolled from two academic hospitals in Wuhan, China, from 01/26/2020 to 03/26/2020. Adjusted in-hospital mortality was compared between the statin and the non-statin group by CHD status using multivariable Cox regression model after propensity score matching. Our study included 3133 COVID-19 patients (median age: 62y, female: 49.8%), and 404 (12.9%) received statin. Compared with the non-statin group, the statin group was older, more likely to have comorbidities but with a lower level of inflammatory markers. The Statin group also had a lower adjusted mortality risk (6.44% vs. 10.88%; adjusted hazard ratio
0.47; 95% CI, 0.29-0.77). Subgroup analysis of CHD patients showed a similar result. Propensity score matching showed an overall 87% (HR, 0.13; 95% CI, 0.05-0.36) lower risk of in-hospital mortality for statin users than nonusers. Such survival benefit of statin was obvious both among CHD and non-CHD patients (HR = 0.30 [0.09-0.98]; HR = 0.23 [0.1-0.49], respectively). Statin use was associated with reduced in-hospital mortality in COVID-19. The benefit of statin was both prominent among CHD and non-CHD patients. These findings may further reemphasize the continuation of statins in patients with CHD during the COVID-19 era.
. 2021 Dec 13;11(1):23874.
doi: 10.1038/s41598-021-02534-2.
Statin Use and In-hospital Mortality in Patients with COVID-19 and Coronary Heart Disease
Lan Shen[SUP] #[/SUP][SUP] 1 [/SUP], Lin Qiu[SUP] #[/SUP][SUP] 2 [/SUP], Li Wang[SUP] #[/SUP][SUP] 3 [/SUP], Hengye Huang[SUP] #[/SUP][SUP] 4 [/SUP], Dong Liu[SUP] 2 [/SUP], Ying Xiao[SUP] 2 [/SUP], Yi Liu[SUP] 2 [/SUP], Jingjin Jin[SUP] 2 [/SUP], Xiulan Liu[SUP] 2 [/SUP], Dao Wen Wang[SUP] 5 [/SUP], Ben He[SUP] 6 [/SUP], Ning Zhou[SUP] 7 [/SUP]
Affiliations
- PMID: 34903765
- DOI: 10.1038/s41598-021-02534-2
Abstract
The worsening progress of coronavirus disease 2019 (COVID-19) is attributed to the proinflammatory state, leading to increased mortality. Statin works with its anti-inflammatory effects and may attenuate the worsening of COVID-19. COVID-19 patients were retrospectively enrolled from two academic hospitals in Wuhan, China, from 01/26/2020 to 03/26/2020. Adjusted in-hospital mortality was compared between the statin and the non-statin group by CHD status using multivariable Cox regression model after propensity score matching. Our study included 3133 COVID-19 patients (median age: 62y, female: 49.8%), and 404 (12.9%) received statin. Compared with the non-statin group, the statin group was older, more likely to have comorbidities but with a lower level of inflammatory markers. The Statin group also had a lower adjusted mortality risk (6.44% vs. 10.88%; adjusted hazard ratio
0.47; 95% CI, 0.29-0.77). Subgroup analysis of CHD patients showed a similar result. Propensity score matching showed an overall 87% (HR, 0.13; 95% CI, 0.05-0.36) lower risk of in-hospital mortality for statin users than nonusers. Such survival benefit of statin was obvious both among CHD and non-CHD patients (HR = 0.30 [0.09-0.98]; HR = 0.23 [0.1-0.49], respectively). Statin use was associated with reduced in-hospital mortality in COVID-19. The benefit of statin was both prominent among CHD and non-CHD patients. These findings may further reemphasize the continuation of statins in patients with CHD during the COVID-19 era.